Výsledky vyhledávání - "Yasmin J, Asad"

Supplementary Table 1 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Autor: Florence I. Raynaud, Johann S. de Bono, Paul Workman, Stan B. Kaye, Suzanne A. Eccles, Bart Vanhaesebroeck, Mika Derynck, Lori Friedman, Richard D. Baird, Alexis de Haven Brandon, Gary Box, Melanie Valenti, Alan T. Henley, Yasmin J. Asad, Joo Chew Ang, Rupinder Pandher, Joo Ern Ang

Metabolite changes that constitute the Venn diagram in Figure 2. Significant changes listed are reductions (labelled "-1") or increases (labelled "1") in concentrations relative to the relevant controls.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35242fa0e3a742cbb6b034b2187e5495
https://doi.org/10.1158/1535-7163.22503601

Zobrazit plný text záznamu

Supplementary Table 3 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Characteristics of dose-dependent changes in candidate plasma metabolite pharmacodynamic biomarker concentrations in 41 patients, as determined on day 1 of pictilisib clinical trial. Cells with p-values

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4068e9bc95db86ee6248750810664f56
https://doi.org/10.1158/1535-7163.22503595

Zobrazit plný text záznamu

Supplementary Table 2 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Summary of baseline reproducibility of candidate plasma metabolite biomarkers (n=17 patients).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca4f1e3fff57a56a184d3e834e92b978
https://doi.org/10.1158/1535-7163.22503598.v1

Zobrazit plný text záznamu

Supplementary Table 4 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Changes in candidate plasma metabolite pharmacodynamic biomarker concentrations over first 2 weeks in 17 patients treated with {greater than or equal to}330 mg once-daily of pictilisib. Cells with p-values

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::146f091d32f617a6f33545ed2ab9f842
https://doi.org/10.1158/1535-7163.22503592.v1

Zobrazit plný text záznamu

Supplementary Figure 1 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Heat map of changes (relative to vehicle control) in candidate plasma and tumor metabolite biomarkers at 8 hours post-dosing of mice bearing U87MG xenografts with pictilisib 75mg/kg or buparlisib 60mg/kg (a, acyl; aa, acyl-acyl; ae, acyl-alkyl; Cx:y,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::783e2038908da754470e738776ff331e
https://doi.org/10.1158/1535-7163.22503604

Zobrazit plný text záznamu

Supplementary Table 5 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Changes in plasma metabolites across timepoints by patient/sample.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3403e56e36b8dc398b621ff78430c7a3
https://doi.org/10.1158/1535-7163.22503589.v1

Zobrazit plný text záznamu

Supplementary Table 1 from Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Autor: Florence I. Raynaud, Udai Banerji, Paul Workman, Stanley B. Kaye, Johann S. de Bono, Suzanne A. Eccles, Valerie Meresse, Ruediger Rueger, Miro Venturi, Debra J. Skene, Victoria L. Revell, Alexis de haven Brandon, Gary Box, Melanie Valenti, Alan T. Henley, Yasmin J. Asad, Akos Pal, Joo Ern Ang

Time of day variation in metabolites in healthy volunteers and in patients treated with the MEK inhibitor.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83107465c9a5097e379e6d18c459f627
https://doi.org/10.1158/1535-7163.22508289.v1

Zobrazit plný text záznamu

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Autor: Joo Ern, Ang, Akos, Pal, Yasmin J, Asad, Alan T, Henley, Melanie, Valenti, Gary, Box, Alexis, de Haven Brandon, Victoria L, Revell, Debra J, Skene, Miro, Venturi, Ruediger, Rueger, Valerie, Meresse, Suzanne A, Eccles, Johann S, de Bono, Stanley B, Kaye, Paul, Workman, Udai, Banerji, Florence I, Raynaud

Publikováno v: Molecular cancer therapeutics. 16(10)

MAPK pathway activation is frequently observed in human malignancies, including melanoma, and is associated with sensitivity to MEK inhibition and changes in cellular metabolism. Using quantitative mass spectrometry-based metabolomics, we identified

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::54b8fef7d9d690fb158905d9af8f3cda
https://pubmed.ncbi.nlm.nih.gov/28637716

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání